Filters

HPV33 E6 Antibody, FITC Conjugated

HPV33 E6 Antibody, FITC Conjugated size: 0.1ml 333

Supplier BIOSS PRIMARY CONJUGATED ANTIBODIES 1
Price 333
Size 0.1ml
Contact us Ask Component cell markers and DNA bp. markers are genetic markerser genes or DNA sequenceswith selection audit
Long name FITC Conjugated, HPV33 E6 Polyclonal Antibody
CategoryConjugated Primary Antibodies
ConjugationAnti-FITC Antibody
Host OrganismRabbit (Oryctolagus cuniculus)
Target AntigenHPV33 E6
Specificity HPV58, This antibody will detect E6 in HPV33, and Alphapapillomavirus 9, This is a highly specific antibody against HPV33 E6
ModificationUnmodified
Modification siteNone
ClonalityPolyclonal
ClonePolyclonal antibody
Concentration1ug per 1ul
Immunogen_range90-140/149
Subcellular locationNucleus
SourceKLH conjugated synthetic peptide derived from human HPV33 E6 protein
Tested applicationsIF(IHC-P)
Recommended dilutionsIF(IHC-P)(1:50-200)
CrossreactivityVirus
Crossreactive species details Alphapapillomavirus 9, HPV58, HPV33
Antigen background 31 and 33, Approximately 90% of cervical cancers contain HPV DNA of the high risk types, Binds double-stranded DNA, HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types, However, Human papillomaviruses (HPV) are small DNA viruses which infect epithelia of the skin and mucosa, Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function, Over 90 types have been identified and they mostly cause a variety of benign lesions such as warts and verrucae, The E6 protein is a transcriptional transactivator, The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, The specific interactions of the E6 and E7 proteins with p53 and pRB, This protein may be involved in the oncogenic potential of this virus (cervical neoplasia-associated virus), and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro, correlate with HPV high and low risk classifications, have been confirmed as agents which cause cervical cancer, notably types 16 and 18, respectively, some subtypes, Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer
Purification methodThis antibody was purified via Protein A
Storage conditions 50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA
Excitation Emission494nm/518nm
Synonyms HPV33 E6 protein, HPV33-E6 protein, Human Papilloma Virus, Human papillomavirus type 33, Human papillomavirus type 33, Protein 33, VE6_HPV33, E6 protein [Human papillomavirus type 33]
Properties Bioss Primary Conjugated Antibodies FITC is highly sensitive to pH extremes, FITC has a green emission that's usually collected at 530 nanometers, FITC has a high quantum yield (efficiency of energy transfer from absorption to emission fluorescence) and approximately half of the absorbed photons are emitted as fluorescent light, For fluorescent microscopy applications, This Bioss Primary Conjugated Antibodies Fluorescein isothiocyanate (FITC) antibody is currently after some BD antibodies the most commonly used fluorescent dye for FACS, When excited at 488 nanometers, its photo bleaching effects are not observed due to a very brief interaction at the laser intercept, the 1 FITC is seldom used as it photo bleaches rather quickly though in flow cytometry applications, the FL1 detector of a FACSCalibur or FACScan, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°
Gene targetHPV33 E6 Conjugated
Short name FITC Conjugated, HPV33 E6 Antibody
Technique Fluorescein, antibodies against human proteins, antibodies for, antibody Conjugates, Antibody
LabelFITC
Alternative name fluorecein coupled, HPV33 E6 (Antibody to)
Alternative techniqueantibodies

Similar products

Subscribe to our Newsletter